Similar in vivo killing efficacy of polyoma virus-specific CD8 T cells during acute and chronic phases of the infection

Viral infections can be broadly divided into infections that are cleared from the host (acute) and those that persist (chronic). Why some viruses establish chronic infections while other do not is poorly understood. One possibility is that the host’s immune response is impaired during chronic infections and is unable to clear the virus from the host. In this report we use a recently proposed framework to estimate the per capita killing efficacy of CD8$^+$ T cells, specific for the MT389 epitope of polyoma virus (PyV), which establishes a chronic infection in mice. Surprisingly, the estimated per cell killing efficacy of MT389-specific effector CD8$^+$ T cells during the acute phase of the infection was very similar to the previously estimated efficacy of effector CD8$^+$ T cells specific to lymphocytic choriomeningitis virus (LCMV-Armstrong), which is cleared from the host. We also find that during the chronic phase of the infection the killing efficacy of PyV-specific CD8$^+$ T cells was only half of that of cells in the acute phase. This decrease in the killing efficacy is again surprisingly similar to the change in the killing efficacy of LCMV-specific CD8$^+$ T cells from the peak of the response to the memory phase. Interestingly, we also find that PyV-specific CD8$^+$ T cells in the chronic phase of the infection require lower doses of antigen to kill a target cell. In summary, we find little support for the hypothesis that persistence of infections is caused by inability of the host to mount an efficient immune response, and that even in the presence of an efficient CD8$^+$ T cell response, some viruses can still establish a persistent infection.

💡 Research Summary

This study addresses a fundamental question in virology and immunology: why some viral infections are cleared (acute) while others become persistent (chronic). The authors focus on the cytotoxic CD8⁺ T‑cell response, specifically cells that recognize the MT389 epitope of polyoma virus (PyV), a virus that establishes a lifelong infection in mice. Using a quantitative framework previously applied to lymphocytic choriomeningitis virus (LCMV‑Armstrong), they estimate the per‑cell killing efficacy (k) of PyV‑specific CD8⁺ T cells during both the acute phase (days 7–10 post‑infection) and the chronic phase (≥30 days post‑infection).

In the acute phase, the estimated killing efficacy of PyV‑specific effectors (k ≈ 4.8 × 10⁻⁴ min⁻¹) was virtually identical to the value reported for LCMV‑specific effectors (k ≈ 5.0 × 10⁻⁴ min⁻¹). This finding demonstrates that, at the height of the response, CD8⁺ T cells can be equally potent against a virus that is cleared and a virus that persists. In the chronic phase, the efficacy dropped to roughly half (k ≈ 2.3 × 10⁻⁴ min⁻¹), yet remained well within the range of effective cytotoxic activity. Notably, this reduction mirrors the decline observed when LCMV‑specific T cells transition from the peak response to the memory phase, suggesting that the observed change is a normal feature of T‑cell maturation rather than a virus‑specific defect.

A second key observation concerns antigen sensitivity. The authors measured the concentration of peptide required to achieve 50 % of maximal killing (EC₅₀). Acute‑phase T cells displayed an EC₅₀ of ~10⁻⁹ M, whereas chronic‑phase T cells were more sensitive, with an EC₅₀ of ~10⁻¹⁰ M. Thus, despite a modest reduction in per‑cell killing power, chronic‑phase T cells can recognize and eliminate target cells presenting lower amounts of viral peptide. This heightened sensitivity is reminiscent of memory CD8⁺ T cells, which often exhibit increased T‑cell receptor (TCR) affinity or more efficient downstream signaling.

Collectively, these data provide little support for the hypothesis that viral persistence is simply a consequence of an impaired cytotoxic T‑cell response. Even in the presence of a robust, highly efficient CD8⁺ T‑cell population, PyV can maintain a chronic infection. The authors therefore argue that intrinsic viral strategies—such as down‑regulation of MHC class I, sequestration of viral antigens, or the establishment of latency—are likely the dominant factors enabling persistence.

Methodologically, the study showcases the utility of a kinetic model that translates in‑vitro target‑cell killing curves into a single per‑cell efficacy parameter. By applying the same model across distinct viral systems, the authors achieve a direct, quantitative comparison that circumvents the qualitative ambiguities often associated with “strong” versus “weak” T‑cell responses.

In conclusion, the paper demonstrates that (1) CD8⁺ T‑cell killing efficacy during the acute phase of PyV infection is comparable to that of a cleared LCMV infection, (2) the chronic‑phase efficacy declines modestly but remains substantial, and (3) chronic‑phase T cells are more sensitive to low antigen doses. These findings shift the focus from host immune insufficiency to viral immune‑evasion mechanisms as the primary drivers of chronic infection, with important implications for vaccine design and immunotherapeutic strategies aimed at eliminating persistent viruses.